Focus Stocks
Is Amgen Waiting for a Break Out?
Published on Tuesday, 29 January 2013 06:52 Written by TradersHuddle Wire
New York, January 29th (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) ended the trading session at $85.59, near its 50 day moving average set at $87.01. Amgen's price action placed the stock below this important level, which makes it difficult to be bought, as the stock will certainly face resistance as it approaches its 50 day moving average.
Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The company concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
The latest price action range, defined by a peaks and troughs algorithm, placed calculated support at $81.56 and resistance at $89.58. These levels will be closely monitored, as they provide great insight into the latest price dynamics.
If traders want to establish a position in Amgen, given the resistance expected as the stock approaches its 50 day moving average, a trade might materialize as the stock manages to break this important technical level. After the breakout, the 50 day moving average could be used as support going forward. However, until the break materializes, buying the stock is basically a gamble with 50-50 chance.
Related Articles
- Approaching Support: Amgen
- Is Amgen Close to Support?
- Amgen Is Close to its 200 Day Moving Average
- Amgen Broke Support
- Trading the Setup In Amgen
- Approaching Support: Amgen
- Amgen Is Close to the 50 Day Moving Average
- Trading the Setup In Amgen
- NASDAQ 100 Round Up - Flat: FSLR, CTRP, BIDU
- Reference Points for Amgen
Related Partner Headlines
- Cramer's Top Stock Picks: AMGN, HPY, but Avoid JCP - TheStreet.com
- Amgen Stock To Go Ex-dividend Tomorrow (AMGN) - TheStreet.com
- Amgen Inc (AMGN): Today's Featured Drugs Winner - TheStreet.com
- Amgen Inc Stock Buy Recommendation Reiterated (AMGN) - TheStreet.com
- Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial Did Not Meet Primary Endpoint - Benzinga
- Amgen Inc Stock Buy Recommendation Reiterated (AMGN) - TheStreet.com
- UPDATE: Oppenheimer Raises PT to $89 on Amgen - Benzinga
- UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Amgen - Benzinga
- Amgen's Third Quarter Earnings Report - Investopedia
- Analysts' Actions: CAT AMGN DNKN BTU COF - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,179.85 Trade time:4:33PM EDT Value change:▲109.67 (0.73%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,639.04 Trade time:4:33PM EDT Value change:▲12.31 (0.76%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,452.13 Trade time:5:15PM EDT Value change:0.00 (0.00%)In The Wires
-
LDK Solar Announces Next Generation of Modules -
Epson Launches New Online Portal for Real Estate Professionals -
China's CITIC Offshore Helicopter Company to Acquire Two S-92® Helicopters -
Raytheon delivers first Standard Missile-3 from new Alabama missile integration facility -
UTC Aerospace Systems recognized as top 10 Airbus supplier for aftermarket support for fifth consecutive year -
UTC Aerospace Systems supports Airbus A400M certification and first production delivery -
A Leading Financial Institution in the US Selected Sapiens DECISION -
Raytheon extends ballistic missile defense capability through radar modernization effort








